Rheumatology Advance Access originally published online on March 9, 2006
Rheumatology 2006 45(9):1144-1147; doi:10.1093/rheumatology/kel039
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period
Centre for Rheumatology Research, Division of Medicine, University College London, London, UK and 1Department of Nephrology, Royal Free Hospital NHS Trust, London, UK.
Correspondence to: D. Isenberg, Centre for Rheumatology Research, Division of Medicine, Room 331, 3rd Floor, Windeyer Building, 46 Cleveland Street, London W1T 4JF, UK. E-mail: d.isenberg{at}ucl.ac.uk
Objectives. Although the prognosis for patients with renal lupus has improved, a small number still progress to renal failure. Studies from the USA have found it difficult to distinguish whether the higher rate of renal failure in African-Americans is due to genetic or socio-economic factors. Our aim was to identify ethnic and other factors in a UK lupus cohort that contribute to renal failure.
Methods. The University College London (UCL) Hospitals lupus cohort of 401 patients (Whites 64%, Blacks 19%), followed since 1978, has 127 patients with renal disease, of whom 21 have gone into renal failure. We determined the characteristics and possible causes of renal failure in this group. Black patients were disproportionately represented in the renal failure group (62% vs 19% for Whites).
Results. Those in the renal failure group had persistently low C3 compared with the renal disease cohort. A high proportion of patients in the renal failure group were felt to be non-adherent to treatment.
Conclusions. Given that health-care for patients in the UK is free at the point of delivery, we postulate that in our cohort genetic factors rather than socio-economic status are likely to be more significant in causing renal failure. However, there may be cultural and other reasons for this, which requires further study.
KEY WORDS: Systemic lupus erythematosus, End-stage renal failure, Ethnicity.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. B. Appel, G. Contreras, M. A. Dooley, E. M. Ginzler, D. Isenberg, D. Jayne, L.-S. Li, E. Mysler, J. Sanchez-Guerrero, N. Solomons, et al. Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis J. Am. Soc. Nephrol., May 1, 2009; 20(5): 1103 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Chambers, R. Raine, A. Rahman, and D. Isenberg Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort Rheumatology, March 1, 2009; 48(3): 266 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Cortes, S Chambers, A Jeronimo, and D Isenberg Diabetes mellitus complicating systemic lupus erythematosus - analysis of the UCL lupus cohort and review of the literature Lupus, November 1, 2008; 17(11): 977 - 980. [Abstract] [PDF]
|
|
|
|
|
|
A.M. Bertoli, L.M. Vila, M. Apte, B.J. Fessler, H.M. Bastian, J.D. Reveille, and G.S. Alarcon Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage Lupus, June 1, 2007; 16(6): 410 - 417. [Abstract] [PDF]
|
|
|
|
|
|
S. A. Chambers, A. Rahman, and D. A. Isenberg Treatment adherence and clinical outcome in systemic lupus erythematosus Rheumatology, June 1, 2007; 46(6): 895 - 898. [Full Text] [PDF]
|
|
|
|
|
|
D Isenberg and P Lesavre Lupus nephritis: assessing the evidence, considering the future Lupus, March 1, 2007; 16(3): 210 - 211. [PDF]
|
|